A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Randomized, Open-label Crossover, Food Effect Study of HEC96719 in Healthy Chinese Subjects
Latest Information Update: 10 May 2021
Price :
$35 *
At a glance
- Drugs HEC 96719 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
- 06 May 2021 Status changed from recruiting to completed.
- 04 Nov 2020 Status changed from not yet recruiting to recruiting.
- 15 Sep 2020 New trial record